By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
While UnitedHealth's Q1 results and lower medical cost ratio are positive, the panelists agree that the long-term sustainability of the turnaround depends on CMS MA rate adjustments, pricing discipline, and regulatory risks. The key risk is the potential erosion of Optum Health's margins due to utilization spikes and regulatory pushback, which could undermine the closed-loop thesis.
Risk: Erosion of Optum Health's margins due to utilization spikes and regulatory pushback
Opportunity: Sustained pricing discipline and favorable CMS MA rate adjustments
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
UnitedHealth Group was struggling when Buffett bought the stock last year.
The healthcare giant's Q1 results announced on Tuesday appear to indicate the start of a turnaround.
Buffett's strategy of buying good businesses on sale while ignoring the noise appears to be paying off yet again.
Flashback to the second quarter of last year. The wheels seemed to be coming off for UnitedHealth Group (NYSE: UNH). The healthcare giant first revised its full-year outlook downward, then yanked the guidance altogether. Its CEO was shown the exit door. Reports surfaced about an investigation by the U.S. Department of Justice. UnitedHealth's stock was sinking fast.
But there was at least one major investor who wasn't worried. Warren Buffett initiated a $1.6 billion stake in the health insurance stock for Berkshire Hathaway's (NYSE: BRKA) (NYSE: BRKB) portfolio. Buffett saw an overreaction related to temporary issues facing a company that remained fundamentally strong.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Now, let's return to the present. UnitedHealth Group reported its first-quarter results on Wednesday. And the investing world got to see why Buffett earned the nickname "the Oracle of Omaha." UnitedHealth proved Buffett right -- again.
Berkshire Hathaway is a leader in the property & casualty (P&C) insurance market. Although P&C is different from health insurance, Buffett knew of one common denominator: when insurers' bottom lines suffer, they can nearly always raise rates to fix the problem.
UnitedHealth said last year that it planned to raise rates. It followed through with that promise, and it showed in the Q1 results. The company's medical cost ratio (calculated by dividing total medical care costs by total premium revenue collected, less taxes and fees) fell from 84.8% in the prior-year period to 83.9% in the recent quarter.
This improvement wasn't the result of declining medical costs. Tim Noel, CEO of the company's UnitedHealthcare business, said in the Q1earnings call "We continue to see the utilization patterns continuing with high, elevated levels that we experienced in 2025."
UnitedHealth Group delivered better-than-expected revenue and earnings in Q1. The company also raised its full-year earnings guidance. CEO Stephen Hemsley painted a picture in theearnings callof the early stages of a bona fide turnaround story.
UnitedHealth's Q1 update was a big win for the company and its shareholders. It should also serve as a reminder of why Buffett's investing strategy works.
Buffett didn't pay attention to the noise last year. He didn't worry about the uncertainty. The legendary investor understood UnitedHealth's business well enough to realize that its issues were only temporary. He also did enough research to know the company remained financially strong.
By the way, Buffett didn't panic and sell earlier this year when the Centers for Medicare and Medicaid Services (CMS) announced ridiculously low proposed Medicare Advantage rates for 2027. He waited. CMS ultimately came back with much higher rates.
The big takeaway for investors here is to buy great businesses when they're on sale and hold the stocks through any turbulence. This approach has paid off for Buffett over the long term. It can pay off for other investors, too.
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $499,277! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,225,371!
Now, it’s worth noting Stock Advisor’s total average return is 972% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of April 23, 2026. *
Keith Speights has positions in Berkshire Hathaway. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"UNH's recent margin improvement is a tactical victory in pricing, but it does not resolve the long-term systemic risk of rising medical utilization and unpredictable regulatory intervention."
The article frames UNH’s Q1 performance as a vindication of Buffett’s 'buy the dip' philosophy, but it glosses over the structural fragility of the Medicare Advantage (MA) model. While the medical cost ratio (MCR) improvement to 83.9% is a positive signal of pricing power, it masks the reality that UNH is fighting a war of attrition against rising utilization rates. The regulatory environment remains hostile; relying on CMS to 'come back' with favorable rates is a dangerous dependency. UNH is trading at roughly 18x forward earnings, which is reasonable for a blue-chip, but the margin for error is razor-thin if utilization spikes again or if the DOJ investigation yields meaningful operational constraints.
The bull case ignores that UNH’s sheer scale allows it to absorb regulatory shocks and pricing pressures that would bankrupt smaller managed care peers, effectively creating a permanent moat.
"UNH's MCR improvement via premium increases despite elevated utilization proves its resilient pricing power and supports Buffett's quality-on-sale strategy."
UnitedHealth's Q1 results--MCR down 90bps to 83.9% via rate hikes despite CEO-noted elevated utilization persisting into 2025--delivered revenue/earnings beats and raised FY guidance, validating Buffett's $1.6B stake amid last year's turmoil (guidance cut, CEO exit, DOJ probe). This underscores P&C-like pricing power in health insurance, ignoring short-term noise. Article downplays ongoing utilization pressures and omits CMS 2027 MA rate risks, but Hemsley's turnaround narrative holds if rates stick. Second-order: Potential membership churn from hikes, yet Buffett's hold-through-turbulence thesis shines for long-term holders.
Persistent high utilization could outpace rate remediation if inflation in medical costs accelerates, while unresolved DOJ scrutiny and volatile MA reimbursements threaten sustained margins.
"UNH's Q1 beat reflects pricing power, not operational excellence, and the durability of margin gains depends on whether medical cost inflation stays below rate increases—a bet, not a certainty."
The article conflates two separate things: Buffett's contrarian timing (which worked) and UNH's actual operational fix (which is rate increases, not efficiency gains). The Q1 turnaround is real—medical cost ratio improved 90bps—but this is pricing power, not business improvement. The article omits that CMS rate pressure for 2027 remains unresolved long-term, utilization stays 'elevated' (code for high medical costs), and UNH's margin expansion depends entirely on sustained pricing discipline in a competitive market. The Buffett narrative is seductive but masks that UNH is essentially a pass-through business where cost inflation eventually catches up.
If UNH can sustain 83-84% medical cost ratios through disciplined underwriting and rate increases ahead of competitor moves, the stock re-rates higher—and Buffett's 2024 entry at distressed prices becomes a 3-5 year compounding machine, not a timing call.
"UnitedHealth's Q1 signals a durable turnaround through premium-rate actions and favorable cost trends, supporting the Buffett 'buy great businesses on sale' thesis—yet the upside hinges on sustainable rate increases and muted regulatory risk."
While Q1 beating and a lower medical cost ratio bodes well, the bullish read risks overlooking twists. UnitedHealth’s margin uplift relies on higher premiums, yet utilization remains elevated and health-cost inflation could reaccelerate; the longer-term payoffs depend on CMS MA rate adjustments, risk-adjustment dynamics, and the ability to sustain premium growth in a competitive market. The Buffett angle may have already priced in the turn, and a further rate pullback or regulatory tweaks could squeeze earnings. In short: upgrade potential exists, but the durability of the turnaround remains the critical risk to watch.
Devil's advocate: The Q1 beat could be a tailwind from timing rather than a durable shift, and if CMS 2027 rates disappoint again or if medical cost inflation reaccelerates, UNH's multiple could compress quickly.
"UNH's vertical integration via Optum is a double-edged sword that invites greater regulatory antitrust risk than the insurance business alone."
Claude, you hit on the 'pass-through' nature of UNH, but you're missing the Optum vertical integration play. UNH isn't just an insurer; it's the provider (Optum Health) and the pharmacy benefit manager (OptumRx). This creates a closed-loop system where they capture margin on both sides of the medical cost equation. The risk isn't just CMS rates; it's the escalating antitrust scrutiny on this vertical integration model, which is a much bigger existential threat than simple utilization spikes.
"DOJ antitrust risk is financial, not structural, but Optum Health's internal utilization surge is the real margin threat."
Gemini, Optum's vertical integration is a moat, but calling antitrust 'existential' overstates it—the DOJ probe focuses on MA risk-adjustment upcoding (potential $500M-$1B fines, per filings), not forced divestitures. Unflagged risk: Optum Health's 10%+ care activity growth is fueling its own utilization spike (CEO flagged elective procedures), pressuring segment margins to 14% from 16% peaks, undermining the closed-loop thesis.
"Optum Health's margin erosion despite volume growth suggests the vertical integration moat is weaker than the bull case assumes."
Grok's Optum Health margin compression (16% to 14%) is the real tell nobody's emphasized enough. If vertical integration's supposed edge is capturing margin on both sides, but the provider arm is getting squeezed by its own utilization spike, that's not a moat—it's a treadmill. The closed-loop thesis only works if Optum Health can sustain pricing discipline as a provider. If CMS or commercial payers push back on Optum's care costs, UNH loses the arbitrage. This matters more than DOJ fines.
"Antitrust risk exists but is not existential; the moat depends on Optum Health margin resilience amid payer pressure and potential broader regulatory changes."
Grok, antitrust risk is not existential, but margin resilience is the real pressure point. The closed-loop edge relies on Optum Health preserving provider margins while CMS/payors curb cost growth; if margins stay at ~14% or erode further, the supposed moat weakens even with high utilization. DOJ fines are one thing; a broader regulatory shift or forced divestitures (even partial) could cap multiple appreciation long before MA risk-adjustment reforms play out.
While UnitedHealth's Q1 results and lower medical cost ratio are positive, the panelists agree that the long-term sustainability of the turnaround depends on CMS MA rate adjustments, pricing discipline, and regulatory risks. The key risk is the potential erosion of Optum Health's margins due to utilization spikes and regulatory pushback, which could undermine the closed-loop thesis.
Sustained pricing discipline and favorable CMS MA rate adjustments
Erosion of Optum Health's margins due to utilization spikes and regulatory pushback